Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 22271159)

1.

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.

Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, LaCreta FP, Boulton DW.

Adv Ther. 2012 Feb;29(2):163-77. doi: 10.1007/s12325-011-0098-x. Epub 2012 Jan 19.

PMID:
22271159
2.

Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects.

Sunkara G, Reynolds CV, Pommier F, Humbert H, Yeh C, Prasad P.

Curr Med Res Opin. 2007 Mar;23(3):631-40.

PMID:
17355744
3.

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.

Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW.

Diabetes Obes Metab. 2013 Mar;15(3):280-3. doi: 10.1111/dom.12024. Epub 2012 Nov 19.

PMID:
23061428
4.

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.

Yang L, Li H, Li H, Bui A, Chang M, Liu X, Kasichayanula S, Griffen SC, Lacreta FP, Boulton DW.

Clin Ther. 2013 Aug;35(8):1211-1222.e2. doi: 10.1016/j.clinthera.2013.06.017. Epub 2013 Aug 2.

PMID:
23910664
5.

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D.

J Clin Pharmacol. 2008 Jan;48(1):85-95. Epub 2007 Nov 6.

PMID:
17986525
6.

Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.

Kasichayanula S, Liu X, Zhang W, Pfister M, Reele SB, Aubry AF, LaCreta FP, Boulton DW.

Diabetes Obes Metab. 2011 Aug;13(8):770-3. doi: 10.1111/j.1463-1326.2011.01397.x.

PMID:
21435141
7.

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.

Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ.

Diabetes Obes Metab. 2013 Apr;15(4):316-23. doi: 10.1111/dom.12028. Epub 2012 Nov 22.

PMID:
23094794
8.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW.

Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.

9.

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.

Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW.

Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x.

PMID:
21226818
10.

Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.

Bindschedler M, Degen P, Flesch G, de Gasparo M, Preiswerk G.

Eur J Clin Pharmacol. 1997;52(5):371-8.

PMID:
9272406
11.

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW.

Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. Review.

PMID:
24105299
12.

Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.

Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E.

Postgrad Med. 2012 Nov;124(6):55-72. doi: 10.3810/pgm.2012.11.2613.

PMID:
23322139
13.

Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.

Jung JA, Noh YH, Jin S, Kim MJ, Kim YH, Jung JA, Lim HS, Bae KS.

Clin Ther. 2012 Apr;34(4):958-65. doi: 10.1016/j.clinthera.2012.01.026. Epub 2012 Mar 10.

PMID:
22410289
14.
15.

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW.

Clin Ther. 2011 Nov;33(11):1798-808. doi: 10.1016/j.clinthera.2011.09.011. Epub 2011 Oct 26.

PMID:
22030444
16.

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):520-6. doi: 10.1038/clpt.2008.251. Epub 2009 Jan 7.

PMID:
19129748
17.

Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.

Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, Broedl UC.

Clin Ther. 2013 Mar;35(3):226-35. doi: 10.1016/j.clinthera.2013.02.015.

PMID:
23497760
18.

An interaction study with cimetidine and the new angiotensin II antagonist valsartan.

Schmidt EK, Antonin KH, Flesch G, Racine-Poon A.

Eur J Clin Pharmacol. 1998 Feb;53(6):451-8.

PMID:
9551704
19.

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D.

Curr Med Res Opin. 2007 May;23(5):1131-8.

PMID:
17519080
20.

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.

Gerich JE, Bastien A.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):669-83. doi: 10.1586/ecp.11.54. Review.

PMID:
22111852
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk